Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Abstract Background Diagnosing dementia supports patients’ access to treatment options and social services. The addition of dementia to the risk adjustment model for Medicare Advantage (MA) plan payments, affecting claims beginning in 2019, provided an incentive for MA plans to improve the detection and diagnosis of dementia among their enrollees. The objective of this project is to examine the changes in annual incident dementia diagnoses rates associated with the inclusion of dementia diagnoses in risk adjustment models for Medicare Advantage. Methods We conducted a retrospective study using 2017‐2020 data for community‐dwelling beneficiaries enrolled in TM and MA. We estimated difference‐in‐differences (DiD) models to examine changes in incident dementia diagnosis rates in MA relative to TM before and after 2019. The rate of incident dementia diagnosis in each year among beneficiaries without any dementia diagnosis in the year prior to the year of interest. Results There were 84,997,374 beneficiaries. In regression models that adjusted for beneficiary characteristics and time trends, we find that in response to the payment change, the annual incident dementia diagnosis rates in MA increased by about 0.282 percentage points or 11.5% relative to TM. We further find that the increase in incident dementia diagnosis was concentrated among beneficiaries who were more likely to have undiagnosed dementia, specifically, beneficiaries who were Hispanic or Black, who were ages 85 and over, and who were dual‐eligible/low‐income subsidy. Sensitivity analyses excluding 2020 data and allowing beneficiaries to switch between TM and MA during our sample years finds similar results. Conclusion Financial incentives to detect dementia resulted in more dementia diagnoses, particularly among persons at high risk of dementia and of undetected dementia but also raises concerns about diagnostic upcoding and the potential for over‐diagnosis.

Key findings

Why it matters

This study found that new dementia diagnoses in Medicare Advantage increased after dementia was added to the risk adjustment model for plan payments in 2019. It is about diagnosis coding and payment incentives, not about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 4 year(s) since 2024
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Julie Zissimopoulos: h-index 36 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Haye, S., Jacobson, M., Joyce, G., & Zissimopoulos, J. (2024). Changes to Medicare Advantage Risk Adjustment and Dementia Diagnosis in Older Adults. Alzheimer s & Dementia. https://doi.org/10.1002/alz.089359

Vancouver

Haye S, Jacobson M, Joyce G, Zissimopoulos J. Changes to Medicare Advantage Risk Adjustment and Dementia Diagnosis in Older Adults. Alzheimer s & Dementia. 2024. doi:10.1002/alz.089359.

BibTeX

@article{haye2024-a3d5dc30,
  author  = {Haye, Sidra and Jacobson, Mireille and Joyce, Geoffrey and Zissimopoulos, Julie},
  title   = {{Changes to Medicare Advantage Risk Adjustment and Dementia Diagnosis in Older Adults}},
  journal = {Alzheimer s \& Dementia},
  year    = {2024},
  doi     = {10.1002/alz.089359},
  url     = {https://doi.org/10.1002/alz.089359}
}

Related studies in Health systems and care delivery

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →